Improving the quality of life of patients worldwide

Polysomnography (PSG) is a sleep study in which various physiological parameters are recorded during the patient's sleep. Onera Health is a leader in the development of remote diagnostics and monitoring. The Onera Health product portfolio includes the CE-marked PSG solution Onera STS I for sleep studies in both clinical and non-clinical settings. It is a groundbreaking solution that significantly simplifies the process of conducting a sleep study and delivers the quality of a PSG diagnosis directly to ‘the patient's bed’, whether in a hospital, sleep laboratory, or at home. Enthusiastically, Ruben adds: “Our innovative solutions and services are ready to help millions of people struggling with health problems and chronic conditions. We aim to improve the quality of life for patients worldwide.”

The relationship between Onera and Invest-NL has been established for some time. Ruben: “We have known Invest-NL since its launch. Although Invest-NL is relatively new, it has become an important player in the Dutch technology landscape through various collaborations. The investments pursued by Invest-NL, aiming for both financial and non-financial returns, represent a new – but essential – approach to impact investing. The moment for us to approach Invest-NL was early 2020. We then quickly found common ground for our collaboration: both Invest-NL and Onera are working towards affordable and accessible healthcare.”

Karin and Bram collaborate on special investments in healthcare, such as those by Onera. Karin: “Within our theme of Life Sciences and Health, we want to make an impact by focusing on accessible innovations that positively contribute to reducing healthcare costs for major chronic conditions, while simultaneously providing better care and quality of life. We think of alternative models for drug development and the ‘Right Care at the Right Place’, meaning striving for care at home as much as possible and as little as in academic hospitals. Prevention is very important here. When a proposal comes in, we assess whether it fits within this healthcare strategy.” Bram adds: “We are responsible for deciding whether or not to invest in companies. Specifically, we look for a combination of a strong management team, high impact, a unique product, significant market potential, and a good return expectation.”

There is a confident outlook on the future. Bram: “The goal of Invest-NL's investment is to support Onera in further developing and commercialising its product, thereby achieving the intended impact. This is not just about providing capital. In our view, the value of the collaboration between Onera and Invest-NL also lies in further professionalising the governance and organisation.” Ruben fully agrees: “We are happy to work together to achieve our shared goal of a more sustainable future and a society with equal opportunities for everyone. These are important ingredients for the future of healthcare that we want to realise in the Netherlands and ultimately worldwide.”